2022
Genetic testing in privately insured women with surgically treated breast cancer
Dinan M, Pitafi S, Greenup R, Long J, Gross C. Genetic testing in privately insured women with surgically treated breast cancer. Breast Cancer Research And Treatment 2022, 198: 177-181. PMID: 36542252, DOI: 10.1007/s10549-022-06829-4.Peer-Reviewed Original ResearchConceptsBreast cancerGenetic testingRoutine breast cancer careBRCA1/BRCA2 genetic testingHormone receptor statusBreast cancer careInvasive breast cancerBRCA2 genetic testingReceptor statusWomen 50Cancer careAge 45Family historyOlder womenInsurer databaseYoung womenCancerWomenCoverage policiesUnclear implicationsPatientsSurgeryPurposeRatesYearsPrevalence
2020
Missing data in breast cancer: Relationship with survival in national databases.
Plichta J, Rushing C, Lewis H, Blazer D, Hyslop T, Greenup R. Missing data in breast cancer: Relationship with survival in national databases. Journal Of Clinical Oncology 2020, 38: e19114-e19114. DOI: 10.1200/jco.2020.38.15_suppl.e19114.Peer-Reviewed Original ResearchOverall survivalNational Cancer RegistryTumor variablesCancer RegistryBreast cancerLarge national cancer registryCox proportional hazards modelInvasive breast cancerPatterns of careInclusion/exclusion criteriaTreatment variablesProportional hazards modelRate of deathWorse OSOncology outcomesN stageOS differenceExclusion criteriaOutcome studiesHazards modelPatientsNCDBSurgery dataGreater riskNational database
2017
Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer.
Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R, Coopey S, Taghian A, Hughes K, Isakoff S, Ellisen L, Smith B, Specht M, Moy B, Bardia A. Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer. Journal Of The National Comprehensive Cancer Network 2017, 15: 1216-1223. PMID: 28982747, DOI: 10.6004/jnccn.2017.0158.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsFemaleFollow-Up StudiesHumansMutationNeoadjuvant TherapyNeoplasm GradingNeoplasm StagingRecurrenceRegistriesRetrospective StudiesSurvival AnalysisTreatment OutcomeTriple Negative Breast NeoplasmsYoung AdultConceptsPathologic complete responseDisease-free survivalBaseline clinical stageNeoadjuvant chemotherapyOverall survivalBreast cancerYoung womenComplete responseClinical stageResidual diseaseInvasive breast cancerLong-term outcomesAggressive tumor biologyMassachusetts General HospitalDFS ratesNeoadjuvant therapyOS ratesSurvival outcomesSurrogate markerGeneral HospitalBest therapyHigh riskTrial designRapid triagePatientsBreast Cancer after Augmentation
Cho E, Shammas R, Phillips B, Greenup R, Hwang E, Hollenbeck S. Breast Cancer after Augmentation. Plastic & Reconstructive Surgery 2017, 139: 1240e-1249e. PMID: 28538550, DOI: 10.1097/prs.0000000000003342.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBreast ImplantationBreast ImplantsBreast NeoplasmsCohort StudiesFemaleFollow-Up StudiesHumansIncidenceLogistic ModelsMammaplastyMastectomyMiddle AgedMultivariate AnalysisPostoperative ComplicationsReference ValuesRetrospective StudiesRisk AssessmentStatistics, NonparametricSurgical FlapsTime FactorsTreatment OutcomeUnited StatesConceptsPrior augmentationBreast cancer stageBreast cancerSubglandular augmentationCancer stageImplant placementCLINICAL QUESTION/LEVELPreferred reconstructive methodAdvanced breast tumorsTwo-stage implant reconstructionInvasive breast cancerBreast cancer screeningBreast cancer diagnosisUndergoing mastectomySubpectoral implantsDuctal carcinomaTherapeutic mastectomyCancer screeningTreatment recommendationsImplant reconstructionSubpectoral augmentationAuthors' institutionBreast augmentationMastectomyBreast tumorsTemporal associations between prognostic indicators and overall survival after breast cancer.
Plichta J, Thomas S, Fayanju O, Rosenberger L, Park T, Hyslop T, Greenup R, Hwang E. Temporal associations between prognostic indicators and overall survival after breast cancer. Journal Of Clinical Oncology 2017, 35: e18144-e18144. DOI: 10.1200/jco.2017.35.15_suppl.e18144.Peer-Reviewed Original ResearchOverall survivalReduced overall survivalEndocrine therapyBreast cancerNon-metastatic invasive breast cancerAssociation of OSHormone receptorsTreatment factorsInvasive breast cancerLong-term outcomesInvasive ductal carcinomaMultivariate survival analysisUnderwent lumpectomyTerm outcomesDuctal carcinomaPrognostic indicatorMultiple time pointsBreast oncologistsSurvival analysisChemotherapyTime pointsTumorsCT/Temporal associationSurvival
2015
Performance and Practice Guideline for the Use of Neoadjuvant Systemic Therapy in the Management of Breast Cancer
Holmes D, Colfry A, Czerniecki B, Dickson-Witmer D, Francisco Espinel C, Feldman E, Gallagher K, Greenup R, Herrmann V, Kuerer H, Malik M, Manahan E, O’Neill J, Patel M, Sebastian M, Wheeler A, Kass R. Performance and Practice Guideline for the Use of Neoadjuvant Systemic Therapy in the Management of Breast Cancer. Annals Of Surgical Oncology 2015, 22: 3184-3190. PMID: 26224406, DOI: 10.1245/s10434-015-4753-3.Peer-Reviewed Original ResearchConceptsNeoadjuvant systemic therapyClinical stage IIInvasive breast cancerBreast cancerSystemic therapyAxillary imagingPractice guidelinesStage IIPurposeThe American SocietyAdvanced breast cancerOptimal patient selectionExtent of diseaseSentinel node biopsyBreast-conserving surgeryEvidence-based guidelinesGenetic testing resultsEfficient patient careSystemic stagingAxillary lesionsClinical responseNode biopsyPerioperative managementSurgical morbidityGuideline recommendationsPatient selection
2014
Cost Implications of the SSO-ASTRO Consensus Guideline on Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Stage I and II Invasive Breast Cancer
Greenup R, Peppercorn J, Worni M, Hwang E. Cost Implications of the SSO-ASTRO Consensus Guideline on Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Stage I and II Invasive Breast Cancer. Annals Of Surgical Oncology 2014, 21: 1512-1514. PMID: 24577813, DOI: 10.1245/s10434-014-3605-x.Peer-Reviewed Original Research
2012
Application of ACOSOG Z0011 Criteria Reduces Perioperative Costs
Camp M, Greenup R, Taghian A, Coopey S, Specht M, Gadd M, Hughes K, Smith B. Application of ACOSOG Z0011 Criteria Reduces Perioperative Costs. Annals Of Surgical Oncology 2012, 20: 836-841. PMID: 23010735, DOI: 10.1245/s10434-012-2664-0.Peer-Reviewed Original ResearchMeSH KeywordsAxillaBreast NeoplasmsCombined Modality TherapyCost-Benefit AnalysisFemaleFollow-Up StudiesHumansLymph Node ExcisionLymphatic MetastasisMastectomy, SegmentalNeoplasm Recurrence, LocalNeoplasm StagingPractice Guidelines as TopicPrognosisRetrospective StudiesSentinel Lymph Node BiopsySurvival RateConceptsAxillary lymph node dissectionCompletion axillary lymph node dissectionPerioperative surgical managementOvernight admissionPerioperative costsZ0011 criteriaSurgical managementBreast cancerSentinel lymph node-positive breast cancerLymph node-positive breast cancerNode-positive breast cancerACOSOG Z0011 criteriaACOSOG Z0011 trialOvernight hospital admissionLymph node dissectionRetrospective chart reviewInvasive breast cancerBreast conservation therapyInpatient hospital daysPositive breast cancerExcellent regional controlPositive SLNZ0011 trialEligible patientsNode dissection